Compounded Tirzepatide Cost Breakdown: What You'll Actually Pay in 2026

Compounded tirzepatide sells for $125 a month at one telehealth provider and $349 at another. The molecule is the same. The difference is everything around it.

This compounded tirzepatide cost breakdown is built for the question most pricing pages refuse to answer. Not "what's the cheapest?" but "what will I actually pay in month one, what's bundled into that number, and what does a real 12-month course cost?"

We're writing for self-pay and uninsured readers. No insurance math, no employer-plan tangents, no "prices may vary" hedging. Just line items, per-milligram math, contract clauses, and the dose strategy that decides whether flat-rate or tiered wins for you.

Across this article: current May 2026 prices for eight named providers (Trimi, Henry Meds, Found, Ro, Eden, Hers, Mochi, MEDVi), the 503A regulatory reality post-March 2025, the per-mg formula, restart costs, six contract gotchas, and a seven-step pharmacy verification protocol.

By the end, you'll know what number to compare across providers and which fees actually hit your card.

What Compounded Tirzepatide Actually Costs in 2026

A month of 15 mg tirzepatide uses about $26 in raw active ingredient. Bulk tirzepatide API runs roughly $430 per gram, down 61% from 2022 prices. Everything else covers pharmacy overhead, sterile compounding, the prescriber, supplies, shipping, and margin.

Here's how that translates to current May 2026 pricing across the providers most readers compare.

Provider Monthly Price Pricing Model Notes
Trimi $125 Flat, all doses $1,500/year annual plan
Henry Meds $179 Tiered starter Climbs with dose
Found $179 Annual billing Lower than month-to-month
Ro $199 to $349 Tiered Wider band by dose
Eden $249 first month, $349 ongoing Tiered Triple-accredited pharmacy
Peak Wellness $229 first / $349 ongoing Flat, all doses Named 503A pharmacies + named clinician + dose-independent
Hers $299 Flat
Mochi Health $278 true cost Membership + medication $199 medication + $79 mandatory membership
MEDVi $349 Flat injectable All-inclusive bundling

Two factors explain the spread. Budget providers in the $125 to $179 range bundle less. They lean on async messaging, minimal coaching, and pharmacy partners with tighter margins, often using shared 503A pharmacies like VialsRx (TX State Board #35264) or GreenwichRx. Premium providers at $349 and up include more clinical oversight, accreditation costs (Eden carries triple accreditation across NABP, PCAB, and ACHC), tighter chain-of-custody documentation, and broader support infrastructure. You're paying for service tier, not molecule.

Peak Wellness is the cleanest mid-tier example of the flat-rate model. At $229 first month and $349 ongoing across every dose tier from 2.5mg to 15mg, it sidesteps the dose-escalation penalty Eden and Ro charge as you titrate. The pharmacy network is fully named publicly (Epiq Scripts, Southend Pharmacy, AbsoluteRx, Emerald Compounding) with zero disciplinary actions on file, and the prescribing clinician (Dr. TelX) is named with credentials on the patient site. That combination — flat pricing plus full pharmacy and clinician disclosure — is rare in the category.

The Empower Pharmacy concentration data tells the same story from the supply side. A 4 mL vial at 17 mg/mL contains 68 mg of tirzepatide. A 2.5 mL vial at 8 mg/mL contains 20 mg. A 2 mL vial at 17 mg/mL contains 34 mg. Same molecule, different fills, very different per-milligram economics. Some providers ship the bigger vial at the higher price; others ship the smaller vial at a lower price and let you assume you got a better deal.

Quick read: Trimi wins on sticker. MEDVi wins on bundling. Mochi wins on neither once the membership fee is counted.

What "Compounded Tirzepatide" Actually Means in 2026

The compounded tirzepatide on the market today isn't the compounded tirzepatide of 2024.

The regulatory timeline matters because it explains what you can actually buy. On December 19, 2024, the FDA declared the tirzepatide shortage resolved. Enforcement discretion ended for 503A pharmacies on February 18, 2025. It ended for 503B outsourcing facilities on March 19, 2025. On April 30, 2026, the FDA proposed permanently excluding tirzepatide, semaglutide, and liraglutide from the 503B Bulks List under Federal Register Docket 2026-08552.

503B scale compounding is shut down. The surviving pathway is narrow. A 503A pharmacy can still compound tirzepatide for an individual patient when there's documented clinical justification, like an allergy to an inactive ingredient in Zepbound or Mounjaro. The FDA was explicit that cost savings does not qualify. In their words, pricing barriers are "a payer problem, an employer problem, a Medicare statutory problem, or a manufacturer pricing problem. It does not become an FDA problem solved through bulk compounding." If you need to qualify for a personalized formulation, our step-by-step guide to getting prescribed compounded tirzepatide walks the eligibility pathways.

That's why your compounded tirzepatide today is a "personalized formulation," with B12, B6, glycine, or niacinamide added. B12 is positioned as energy support and a hedge against GLP-1 nutrient depletion. B6 is added to reduce nausea. Glycine acts as a chemical stabilizer. Niacinamide is anti-inflammatory. The doses are too low to produce major clinical effects. The primary purpose is regulatory: the additives create a product "not identical" to Zepbound, which historically supported a compounding rationale.

The trade-off is real. Eli Lilly tested 10 compounded tirzepatide-plus-B12 samples and found all 10 contained measurable levels of an unknown impurity formed by a tirzepatide-B12 reaction — see our deep-dive on batch-to-batch compounded variability. Nothing is published about this impurity's toxicology, immune profile, or pharmacokinetics.

The verdict: compounded tirzepatide in 2026 is legally a different product than Zepbound, and you're paying for that legal-and-formulation distinction as much as for the molecule itself.

Your Real First-Month Total, Itemized

The number on the pricing page isn't the number that hits your card in month one.

The real first-month cost is built from six line items:

  • Initial consultation: $0 to $99 (most providers waive)
  • First vial or medication: $125 to $349
  • Syringes, alcohol pads, BAC water: $0 to $15 (often included)
  • Baseline labs: $0 to $300 (only if required)
  • Cold-chain shipping: $0 to $25 (most include)
  • Mandatory membership or platform fee: $0 to $99

Two scenarios show how wide the spread runs.

Scenario A: Trimi at $125 flat. Medication $125, consult included, supplies included, shipping included, no labs required by default. First-month total: $125.

Scenario B: MEDVi at $349 injectable. Medication $349, consult included, supplies included, cold-chain shipping included. Labs aren't universal at MEDVi; they're required only when medical history flags thyroid issues, diabetes, or kidney problems. First-month total: $349 to $649 depending on whether labs are needed.

The headline-price comparison ($125 vs $349) misses what's bundled. Trimi looks 64% cheaper, and at base it is. If your medical history triggers labs at a budget provider that charges separately, the gap closes fast.

HSA and FSA dollars cut the effective cost on either scenario by 25 to 30%. We cover that math in the discounts section below.

If you're comparing two providers, ask both for the all-in first-month number and the all-in month-two number. Don't compare base prices.

The Only Fair Way to Compare: Price Per Milligram

Cheap on the sticker isn't always cheap in the vial.

Empower Pharmacy publishes specific concentrations that make per-milligram math possible. A 4 mL vial at 17 mg/mL holds 68 mg of tirzepatide total. A 2.5 mL vial at 8 mg/mL holds 20 mg. A 2 mL vial at 17 mg/mL holds 34 mg. Same molecule, different totals.

The math is simple. Monthly price divided by milligrams shipped equals your true per-milligram cost.

Vial Monthly Price Total mg Per-mg Cost
75 mg vial bulk purchase $550 75 $7.33
Subscription, 4 mL @ 17 mg/mL $349 68 $5.13
Subscription, 2 mL @ 17 mg/mL $349 34 $10.26
Subscription, 2.5 mL @ 8 mg/mL $199 20 $9.95

Notice the trap. A $199 plan with a 20 mg vial is $9.95/mg. A $349 plan with a 68 mg vial is $5.13/mg, less than half the per-milligram rate, despite the higher sticker. The "cheaper" plan is more expensive per milligram if you're titrating to therapeutic doses.

Flat-rate plans only look cheap when you use all the milligrams. At a low microdose, you've paid for medication you'll never inject, which we model in the microdosing section below.

Two providers can quote the same $349 and ship you wildly different amounts of medication. Always ask: how many milligrams am I getting in this vial?

Flat-Rate vs Tiered Pricing: Who Wins

Flat-rate plans charge the same whether you're at 2.5 mg or 15 mg. Tiered plans start cheaper and get more expensive as you titrate up. The right one for you depends on where you end up.

Run the math on a six-month titration to 15 mg.

Flat-rate at $349/mo: $349 × 6 = $2,094 over six months. $4,188 over twelve months.

Tiered at $299 / $399 / $499: $299 × 2 + $399 × 2 + $499 × 2 = $2,394 over six months. The tiered plan looks cheaper at the start, then loses by $300 over six months because the highest tier is $150 above the flat rate.

Flip the scenario. A patient who plans to stay at 2.5 to 5 mg long-term (microdose-and-hold) on the tiered plan pays $299/mo versus $349 flat. Tiered saves $50/mo, $600/year.

The break-even rule: flat-rate wins once you spend more than three months in the highest tier. If your weight loss goal is under 10% of body weight, you probably won't need to escalate that far, and tiered usually wins. If your goal is 15% or more, you'll likely live in the top tier for months, and flat-rate wins.

Flat-rate also removes the dose-escalation cost anxiety that keeps some patients stuck at sub-therapeutic doses. If you're worried that escalating to 10 mg will break the budget, you're probably going to under-titrate. A flat plan takes that decision off the table.

Pick flat-rate if you expect to titrate to therapeutic doses (10 mg or above). Pick tiered if you expect to hold low.

Microdosing as a Cost Lever: 12 to 18 Month Course Math

Most pricing articles assume you'll titrate all the way to 15 mg. Many of our patients never need to.

Microdosing here means 0.5 to 1.5 mg weekly, sustained, below the FDA 2.5 mg starter dose. Dr. Craig Koniver's protocol targets women at ~1.5 mg and men at ~1.8 mg, scheduling escalations during the follicular phase for better GI tolerance.

The cost model breaks open at 18 months.

  • 12-month full-titration via compounding: ~$3,900 to $5,400
  • 18-month microdose-and-hold via compounding: ~$2,700 to $4,500
  • 12-month full-titration via brand Zepbound: ~$12,000+

Zoom in on six months. A 1 mg weekly compounded course runs $900 to $1,500 total. Six months on LillyDirect Self-Pay vials (dividing 2.5 mg vials) costs ~$1,794. Standard compounded dosing over the same span runs $2,094 to $2,994.

Trade-offs are real. Weight loss at 1 mg/week tracks 2 to 4 lbs/month; at 0.5 mg, 1 to 2 lbs/month. No published RCT exists below 2.5 mg, so microdosing is extrapolated from SURMOUNT-1 dose-response data. Bryan Johnson halted his 0.5 mg/week protocol after three weeks: resting heart rate up 3 bpm, HRV down 7 points, sleep down 10%. GLP-1 agonists elevate resting heart rate by 2 to 10 bpm even at sub-therapeutic doses.

Pricing-model interaction matters. Flat-rate plans don't reward microdosing; you still pay $349/mo for medication you don't fully use. Tiered plans capture the savings of holding low.

Best for: under 10% body weight goals, side-effect-sensitive patients, long-term maintenance after primary weight loss. Skip if: 15%+ weight loss target, type 2 diabetes management, hard timeline under 90 days.

What Stopping and Restarting Costs You

Pausing tirzepatide for a few months to save money sounds reasonable. Then you find out you're starting over.

The restart protocol is dose-dependent on how long you've been off.

  • Under 2 weeks off: Resume previous dose with provider confirmation. No re-titration.
  • 2 weeks to 3 months off: Restart one dose level below where you stopped. Minimum 4 weeks before escalating.
  • Over 3 months off: Restart at 2.5 mg. Minimum 20 weeks of re-titration to reach 15 mg again.

Run the math on a three-month pause. You save ~$1,000 in avoided medication during the break (three months at $349). You then face five months of re-titration back to your therapeutic dose. On a flat-rate plan, those five months cost the same as high-dose months ($1,745). On a tiered plan, they're cheaper ($1,495) but extend total treatment timeline by months.

Either way, many patients lose money on the pause and lose months of momentum. Appetite suppression and metabolic benefit aren't there during re-titration, so weight you lost can creep back while you climb the ladder.

There's a better play. Microdosing acts as a financial bridge. Holding at 0.5 to 1 mg weekly maintains some metabolic benefit and avoids the reset. You're spending $146 to $250/mo instead of zero, but not surrendering five months to re-titration.

If you can't afford full dosing, microdose. Don't stop. The restart costs more than the savings.

The Contract Clauses That Cost You Money

The cheapest provider on paper can get expensive once you read the cancellation page.

Six gotchas show up across the major providers, and any one of them can flip your effective cost.

1. Two-subscription cancellation traps. Mochi Health is the named example. Cancelling the prescription doesn't cancel the $79/mo membership. Patients filed 1,294 BBB complaints over three years, many tied to charges that continued after a "successful" cancellation.

2. Auto-renewal defaults. Most plans auto-renew monthly. Some annual plans auto-renew the full year, locking you in for another 12 months if you miss the cancellation window.

3. Cancellation notice windows. Typically 7 to 30 days before next billing. Miss it, and you're billed for the next cycle.

4. Refund policies on shipped vials. Most providers won't refund a shipped vial, even one that hasn't arrived. Some refund unshipped pre-paid vials. Ask before paying annual.

5. Dose-escalation pricing changes. Tiered plans bill the new tier the moment you escalate, often without 30-day notice. A one-week dose change can move you to the next tier for the entire month.

6. Hidden fees. A 2025 Consumer Reports analysis found hidden fees add 15 to 30% across GLP-1 telehealth, via separate consult fees ($50 to $150/mo), supply charges ($20 to $40/mo), shipping ($15 to $25/mo), or membership fees ($99 to $199/mo).

Before signing, ask in writing: the cancellation notice window, the refund policy on shipped product, and whether any second subscription exists alongside the medication.

Skip any provider that won't put their cancellation policy in plain English on the pricing page.

Discounts That Actually Work and Ones That Don't

GoodRx and SingleCare do not work on compounded tirzepatide. They never have. Compounding pharmacies aren't in their networks, and GoodRx coupons only apply at retail chain pharmacies dispensing commercially manufactured FDA-approved drugs.

GoodRx can reduce brand Zepbound retail to roughly $800 to $1,100/mo, a 15 to 20% discount, still well above compounded pricing. The Lilly $25 savings card for brand Zepbound requires commercial insurance, so it's not a self-pay tool.

What does work for compounded:

HSA and FSA pre-tax dollars. With a valid prescription, compounded tirzepatide qualifies as an HSA/FSA-eligible expense. At a 25% marginal tax bracket, $349/mo becomes ~$262 effective. At 30%, ~$244. Annual savings: $1,047 to $1,256 on a $349/mo plan.

Medicare for OSA-qualifying patients. Starting April 2026, Zepbound is covered for moderate-to-severe obstructive sleep apnea with obesity at roughly $50/month copay. The BALANCE Model expansion in January 2027 widens that to obesity with comorbidities. For qualifying patients, that pathway competes directly with most compounded options.

If you have an HSA or FSA, use it before anything else. It's a 25 to 30% discount with no downside.

How to Verify a Compounding Pharmacy Is Legitimate

Between March and August 2025, 120 kilograms of tirzepatide labeled "for compounding" shipped from unregistered facilities in China into the US supply chain, per the Partnership for Safe Medicines six-month report. The FDA issued over 50 warning letters to GLP-1 compounders and telehealth distributors in 2025 alone, and the Lilly v. Henry Meds litigation is testing how the legal frame holds. MEDVi received FDA warning letter #721455 on February 20, 2026 for misbranding violations.

These aren't theoretical risks. Run all seven checks before your first order. The full process is laid out in our pharmacy verification framework, but the short version:

  1. Ask your provider for the pharmacy name and state. Refusal to disclose is the only red flag you need. Walk away.
  2. Search the state pharmacy board website for that pharmacy's home state. Every state has a license lookup, and an active license in good standing is the floor, not the ceiling.
  3. For 503B facilities, check FDA's Registered Outsourcing Facilities list at fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities.
  4. Check NABP's Drug Outlet Verification program at nabp.pharmacy for PCAB or accreditation status.
  5. Request a Certificate of Analysis (CoA) for your specific lot. A real CoA shows lot number, expiration date, potency results, and sterility results. A pharmacy that won't produce one for your shipment is a problem.
  6. Search the FDA Warning Letters database at fda.gov for the pharmacy name and the telehealth platform's name.
  7. Verify the salt form is tirzepatide base. Tirzepatide sodium and tirzepatide acetate are unapproved salt forms and a red flag for unregistered overseas API.

These checks take about 20 minutes. They're free. Run them all before paying for a first month, not after.

The Bottom Line

Compare per-milligram, not per-month. A $199 vial with 20 mg costs more per dose than a $349 vial with 68 mg.

Pick flat-rate if you'll titrate to 10 mg or above. Pick tiered if you'll hold low or microdose. Break-even is three months in the top tier.

Use HSA or FSA dollars. Verify the pharmacy with the seven-step checklist before your first order. Microdose if your goal is under 10% body weight. Don't pause to save money; bridge with a microdose.

Flat-rate, dose-independent compounded pricing is the model worth understanding for patients titrating to therapeutic doses. It's how Peak Wellness structures its tirzepatide offering, and it sidesteps the dose-escalation penalty that bleeds budget on tiered plans.

The cheapest sticker isn't the cheapest medication. Compare the right number for your dosing reality.

FAQ

Technically yes, through narrow 503A exceptions only. 503B large-scale compounding ended March 19, 2025. A 503A pharmacy can compound tirzepatide for an individual patient when there's documented clinical justification, like an allergy to a Zepbound or Mounjaro inactive ingredient. The FDA has explicitly stated that cost savings does not qualify. On April 30, 2026, the FDA proposed permanently excluding tirzepatide from the 503B Bulks List.

Why do prices vary so much between providers, $125 to $499 a month?

Raw API costs about $26 worth at 15 mg per month, so the molecule is structurally cheap. The rest covers pharmacy overhead, sterile compounding facility costs, telehealth platform and clinical consultation, ongoing provider messaging, supplies, shipping, and margin. Budget providers ($125 to $179) bundle less. Premium providers ($349+) bundle more clinical oversight, accreditation, and coaching.

Is oral or tablet compounded tirzepatide worth paying for?

Almost certainly not. Tirzepatide is a 4,810-dalton peptide that stomach acid denatures within minutes. Oral bioavailability is estimated under 1%, meaning you'd need a 1,500+ mg oral dose to match a 15 mg injection. No published clinical data supports therapeutic absorption. A class-action lawsuit filed November 2025 alleges MEDVi's $249/mo oral tablets have no scientifically demonstrated absorption mechanism.

Does compounded tirzepatide work as well as brand Zepbound?

For injectable formulations from properly licensed pharmacies, yes, when storage and dose consistency are maintained. A 1,847-person Reddit retrospective found 16.2% mean weight loss at 24 weeks for compounded users versus 19.1% for brand-name. The gap disappeared when controlling for storage compliance and dose consistency, suggesting execution drove the difference, not the drug — see our deep dive on why compounded GLP-1 reports matter more than branded. Oral compounded tirzepatide does not work.

More from VST GLP-1 Safety

Can I use GoodRx or SingleCare on compounded tirzepatide?

No. GoodRx and SingleCare are negotiated rates with retail chain pharmacies for commercially manufactured FDA-approved drugs. Compounding pharmacies don't participate in those networks. GoodRx can cut brand Zepbound retail to $800 to $1,100/mo, still above most compounded pricing. The only meaningful brand discount is Lilly's $25 savings card, which requires commercial insurance.